Imai, Noboru
Isogai, Yuki
Shibasaki, Yoshiyuki
Nakai, Masami
Ishida, Miki
Ning, Xiaoping
Koga, Nobuyuki
Funding for this research was provided by:
Otsuka Pharmaceutical Co., Ltd.
Article History
Received: 11 April 2023
Accepted: 26 July 2023
First Online: 11 September 2023
Declarations
:
: Noboru Imai has received consulting fees from Otsuka Pharmaceutical Co., Ltd., and Sawai Pharmaceutical Co., Ltd.; and payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Otsuka Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Ltd., Eli Lilly Japan K.K., Amgen Inc., Sawai Pharmaceutical Co., Ltd. Yoshiyuki Shibasaki, Yuki Isogai, Masami Nakai, Miki Ishida, and Nobuyuki Koga are full-time employees of Otsuka Pharmaceutical Co., Ltd. Xiaoping Ning is a full-time employee of Teva Branded Pharmaceutical Products R&D, Inc.
: The trial from which data for this analysis were taken was conducted in compliance with the International Conference on Harmonisation Good Clinical Practice Guideline, the Declaration of Helsinki and local regulatory requirements and was approved by an institutional or independent review board or ethics committee. All patients provided written informed consent at enrollment.